Marilyn Albert

MCI due to AD ,[object Object],[object Object],[object Object]

Disclosures ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Working Group Chair: Marilyn Albert Steve DeKosky Dennis Dickson Bruno Dubois Howard Feldman Nick Fox Maria Carrillo Anthony Gamst Dave Holtzman Bill Jagust Ron Petersen Peter Snyder Tony Phelps Bill Thies Sponsored by NIA and Alzheimer’s Association

Charge to Committee ,[object Object],[object Object],[object Object]

Goals of Committee ,[object Object],[object Object],[object Object],[object Object],[object Object]

Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Disease Progression Cognitive Function Progression of Alzheimer’s Disease Pre-clinical MCI due to AD AD Dementia

Criteria for MCI due to AD Clinical Presentation – 4 criteria ,[object Object],[object Object],[object Object],[object Object]

Criteria for MCI due to AD Clinical Presentation – 4 criteria ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Criteria for MCI due to AD Core Clinical Criteria Other Aspects of Evaluation ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Criteria for MCI due to AD Core Clinical Criteria Minimal Differences from Prior MCI Criteria ,[object Object],[object Object],[object Object],[object Object],[object Object]

Criteria for MCI due to AD Clinical and Cognitive Criteria Minimal Differences from Prior Criteria ,[object Object],[object Object],[object Object],[object Object],[object Object]

Biomarkers and MCI due to AD ,[object Object],[object Object],[object Object],Jagust, Fox, Holtzman

Framework for Biomarkers ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Change from initial draft - harmonization-

Role of Biomarkers ,[object Object],[object Object],[object Object],Amyloid angiopathy

Role of Biomarkers ,[object Object],[object Object]

Use of Biomarkers in Research ,[object Object],[object Object],[object Object],[object Object]

Diagnosis of MCI due to AD Levels of Certainty ,[object Object],[object Object],[object Object],[object Object]

Diagnosis of MCI due to AD Levels of Certainty ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Diagnosis of MCI due to AD Levels of Certainty ,[object Object],[object Object],[object Object],[object Object],[object Object]

Diagnosis of MCI due to AD Levels of Certainty ,[object Object],[object Object],[object Object],[object Object],Prodromal AD

Future Directions Issues to be Addressed ,[object Object],[object Object],[object Object]

Hypothetical Model of Biomarkers in AD FDG PET Abnormal Normal Time Pre-symptomatic EMCI LMCI Dementia Function (ADL) Cognitive performance MRI hippocampal volume CSF Tau Jack et al., 2010 Amyloid imaging CSF A  42

Marilyn Albert

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Andere mochten auch

Andere mochten auch (8)

Ähnlich wie Marilyn Albert

Ähnlich wie Marilyn Albert (20)

Mehr von Alzforum

Mehr von Alzforum (20)

Marilyn Albert